Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
about
Prodrug AST-003 Improves the Therapeutic Index of the Multi-Targeted Tyrosine Kinase Inhibitor SunitinibOptimizing systemic therapy for metastatic renal cell carcinoma beyond the first-line setting.Lenvatinib for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma following one prior anti-angiogenic therapy.Clinical development of mTor inhibitors for renal cancer.
P2860
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
description
2014 nî lūn-bûn
@nan
2014 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
name
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@ast
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@en
type
label
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@ast
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@en
prefLabel
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@ast
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@en
P2093
P2860
P1476
Phase I trial of sunitinib and temsirolimus in metastatic renal cell carcinoma.
@en
P2093
Ana Aparicio
Arlene O Siefker-Radtke
Emre Altinmakas
Lianchun Xiao
Matthew T Campbell
Nizar M Tannir
Paul G Corn
Randall E Millikan
Sin Jen Wen
P2860
P304
P356
10.1016/J.CLGC.2014.10.004
P407
P577
2014-10-24T00:00:00Z